C. Twitty

发表

B. Fox, W. Urba, S. Jensen, 2011, Cancer journal.

Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.

D. Jolly, D. Ostertag, O. Diago, 2016, Human gene therapy methods.

Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro

A. Hofacre, L. Mitchell, H. Gruber, 2016, Molecular therapy. Nucleic acids.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.

B. Fox, T. Crocenzi, W. Urba, 2009, Current molecular medicine.

RecurrenceAntigen Loss Results in Murine Melanoma Regulatory T Cells and T Cell-Mediated Increased Frequency of Suppressive

B. Fox, N. Restifo, P. Antony, 2012 .

Increased Frequency of Suppressive Regulatory T Cells and T Cell-Mediated Antigen Loss Results in Murine Melanoma Recurrence

B. Fox, N. Restifo, P. Antony, 2012, The Journal of Immunology.

Signaling through OX40 enhances antitumor immunity.

B. Fox, N. Morris, W. Urba, 2010, Seminars in oncology.

Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.

B. Fox, R. Pierce, A. Daud, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.

R. Weissleder, G. Freeman, R. Pierce, 2022, Immunity.

Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses against Short-lived Proteins through a p62-Dependent Mechanism

B. Fox, S. Jensen, Hong-Ming Hu, 2011, Clinical Cancer Research.

Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses

R. Pierce, A. Daud, L. Fong, 2019, Cancer Immunology Research.

Intratumoral plasmid IL-12 electroporation therapy in advanced melanoma patients induces systemic and intratumoral T cell responses. T cell responses induced by plasmid IL-12 electroporation

R. Pierce, L. Fong, A. Algazi, 2019 .

Development and characterization of a cell line for large‐scale, serum‐free production of recombinant adeno‐associated viral vectors

B. Donahue, T. Harding, R. Snyder, 2004, The journal of gene medicine.

Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity

Daniel T. Fisher, A. Daud, H. Lyerly, 2022, Molecular therapy oncolytics.

Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)

D. O’Connor, C. Twitty, J. Nitzkorski, 2019 .

Successful Anti‐PD‐1 Cancer Immunotherapy Requires T Cell‐Dendritic Cell Crosstalk Involving the Cytokines IFN‐&ggr; and IL‐12

Ralph Weissleder, Gordon J. Freeman, R. Weissleder, 2018, Immunity.

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma

B. Fox, R. Pierce, M. Pittet, 2020, Clinical Cancer Research.

Prognostic Biomarkers for Melanoma Immunotherapy

A. Daud, C. Twitty, L. Huppert, 2020, Current Oncology Reports.

In Situ Transfection of Interleukin 12 Plasmid Enhances Anti-PD-1 Immune Response in Patients with Immunologically Quiescent Melanoma

A. Olshen, B. Fox, M. Pittet, 2019, SSRN Electronic Journal.

Targeting regulatory T cells and other strategies to enable cancer vaccines

R. Puri, B. Fox, W. Urba, 2011 .

Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma

R. Pierce, D. Byrd, A. Daud, 2019, Clinical Cancer Research.

Disruption of TGF-β Signaling Prevents the Generation of Tumor-Sensitized Regulatory T Cells and Facilitates Therapeutic Antitumor Immunity1

B. Fox, E. Walker, C. Poehlein, 2009, The Journal of Immunology.

Antitumor Immunity T Cells and Facilitates Therapeutic Generation of Tumor-Sensitized Regulatory Signaling Prevents the β Disruption of TGF-and

B. Fox, E. Walker, C. Poehlein, 2009 .

Autophagy-assisted antigen cross-presentation

B. Fox, W. Urba, Zhenxian Zhou, 2012, Oncoimmunology.

Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy

B. Fox, R. Pierce, C. Acharya, 2021, Clinical Cancer Research.

Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid).

R. Pierce, A. Daud, R. Connolly, 2017, Immunotherapy.

Abstract P3-09-04: Phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC) (KEYNOTE- 890/OMS-I141)

I. Wapnir, H. Soliman, M. Telli, 2020 .

THE VIABILITY AND PIGXENTATION OF MEXICANUAI)

C. Twitty, Sxoijotl Chiriera, S. Rireyon, 2004 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Cross-presentation of tumor associated antigens through tumor-derived autophagosomes

B. Fox, W. Urba, Hong-Ming Hu, 2009, Autophagy.

Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma Carcinoma

P. Nghiem, U. Parvathaneni, S. Bhatia, 2022 .

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.

R. Weissleder, R. Pierce, M. Pittet, 2022, Immunity.